as of 04-27-2026 3:22pm EST
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
| Founded: | 2011 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 367.7M | IPO Year: | 2021 |
| Target Price: | $7.50 | AVG Volume (30 days): | 89.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $2.59 - $5.70 | Next Earning Date: | 05-05-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 23.09% | Revenue Growth (next year): | 19.57% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Chief Legal Officer
Avg Cost/Share
$5.20
Shares
684
Total Value
$3,554.27
Owned After
345,736
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$5.21
Shares
4,486
Total Value
$23,349.63
Owned After
3,642,481
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$5.20
Shares
608
Total Value
$3,161.72
Owned After
266,388
SEC Form 4
Chief People Officer
Avg Cost/Share
$5.20
Shares
380
Total Value
$1,977.18
Owned After
215,071
SEC Form 4
President
Avg Cost/Share
$5.20
Shares
760
Total Value
$3,954.96
Owned After
681,672
SEC Form 4
Chief Sales Officer
Avg Cost/Share
$5.08
Shares
33
Total Value
$167.69
Owned After
148,197
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$5.00
Shares
17,473
Total Value
$87,401.69
Owned After
3,642,481
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$4.96
Shares
43,129
Total Value
$213,833.58
Owned After
3,642,481
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$4.96
Shares
1,600
Total Value
$7,932.96
Owned After
266,388
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Van Well Daan | SOPH | Chief Legal Officer | Apr 20, 2026 | Sell | $5.20 | 684 | $3,554.27 | 345,736 | |
| Camblong Jurgi | SOPH | Chief Executive Officer | Apr 20, 2026 | Sell | $5.21 | 4,486 | $23,349.63 | 3,642,481 | |
| Menu Philippe | SOPH | Chief Medical Officer | Apr 20, 2026 | Sell | $5.20 | 608 | $3,161.72 | 266,388 | |
| Xu Zhenyu | SOPH | Chief Scientific Officer | Apr 20, 2026 | Sell | $5.21 | 608 | $3,164.82 | 630,888 | |
| Valente Manuela | SOPH | Chief People Officer | Apr 20, 2026 | Sell | $5.20 | 380 | $1,977.18 | 215,071 | |
| Muken Ross | SOPH | President | Apr 20, 2026 | Sell | $5.20 | 760 | $3,954.96 | 681,672 | |
| Puylaert Kevin | SOPH | Chief Sales Officer | Apr 20, 2026 | Sell | $5.08 | 33 | $167.69 | 148,197 | |
| Camblong Jurgi | SOPH | Chief Executive Officer | Apr 15, 2026 | Sell | $5.00 | 17,473 | $87,401.69 | 3,642,481 | |
| Camblong Jurgi | SOPH | Chief Executive Officer | Apr 14, 2026 | Sell | $4.96 | 43,129 | $213,833.58 | 3,642,481 | |
| Menu Philippe | SOPH | Chief Medical Officer | Apr 14, 2026 | Sell | $4.96 | 1,600 | $7,932.96 | 266,388 |
See how SOPH stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "SOPH SOPHiA GENETICS SA - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.